Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-17 6:29 pm Sale | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | EcoR1 Capital LLC | 0 0.000% | -10,630,736![]() (Position Closed) | Filing History |
| 2026-02-17 4:22 pm Purchase | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | TCG Crossover GP II LLC | 13,521,839 9.990% | 4,985,643![]() (+58.41%) | Filing History |
| 2026-02-17 3:22 pm Purchase | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Woodline Partners LP | 10,072,225 7.500% | 4,042,319![]() (+67.04%) | Filing History |
| 2026-02-13 11:47 am Purchase | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Invus Public Equities, L.P. | 8,165,374 6.100% | 2,282,186![]() (+38.79%) | Filing History |
| 2026-02-12 09:11 am Purchase | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | Adage Capital Management, L.P. | 10,607,924 7.880% | 8,096,924![]() (+322.46%) | Filing History |
| 2026-02-10 4:15 pm Sale | 2026-02-06 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV L.P. | 6,374,574 4.740% | -1,500,000![]() (-19.05%) | Filing History |
| 2026-02-06 4:11 pm Purchase | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | FARALLON PARTNERS L L C | 13,461,215 9.990% | 13,461,215![]() (New Position) | Filing History |
| 2026-01-30 2:44 pm Purchase | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | VANGUARD GROUP INC | 6,750,977 5.010% | 6,750,977![]() (New Position) | Filing History |
| 2026-01-21 12:30 pm Purchase | 2025-12-31 | 13G | Tango Therapeutics, Inc. TNGX | BlackRock Inc. BLK | 8,477,165 6.300% | 3,020,135![]() (+55.34%) | Filing History |
| 2025-11-21 4:15 pm Sale | 2025-11-19 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV L.P. | 7,874,574 5.850% | -1,500,000![]() (-16.00%) | Filing History |
| 2025-11-14 4:23 pm Sale | 2025-09-30 | 13G | Tango Therapeutics, Inc. TNGX | TCG Crossover GP II LLC | 8,536,196 6.300% | -1,964,416![]() (-18.71%) | Filing History |
| 2025-11-14 4:15 pm Sale | 2025-11-12 | 13D | Tango Therapeutics, Inc. TNGX | Third Rock Ventures IV L.P. | 9,374,574 6.970% | -7,626,901![]() (-44.86%) | Filing History |
| 2025-11-13 09:00 am Sale | 2025-09-30 | 13G | Tango Therapeutics, Inc. TNGX | Adage Capital Management, L.P. | 2,511,000 2.260% | -3,394,349![]() (-57.48%) | Filing History |
| 2025-11-12 12:17 pm Purchase | 2025-09-30 | 13G | Tango Therapeutics, Inc. TNGX | Farallon Capital Partners L.P. | 10,757,000 9.700% | 1,600,000![]() (+17.47%) | Filing History |
| 2025-09-22 5:22 pm Purchase | 2025-09-19 | 13G | Tango Therapeutics, Inc. TNGX | Invus Public Equities, L.P. | 5,883,188 5.300% | 5,883,188![]() (New Position) | Filing History |
| 2025-08-14 11:56 am Purchase | 2025-06-30 | 13G | Tango Therapeutics, Inc. TNGX | Woodline Partners LP | 6,029,906 5.600% | 6,029,906![]() (New Position) | Filing History |
| 2025-08-13 5:00 pm Purchase | 2025-06-30 | 13G | Tango Therapeutics, Inc. TNGX | Farallon Capital Partners L.P. | 9,157,000 8.400% | 1,975,000![]() (+27.50%) | Filing History |
| 2025-08-12 09:06 am Purchase | 2025-06-30 | 13G | Tango Therapeutics, Inc. TNGX | Adage Capital Management, L.P. | 5,905,349 5.450% | 5,905,349![]() (New Position) | Filing History |
| 2025-07-17 8:12 pm Purchase | 2025-06-30 | 13G | Tango Therapeutics, Inc. TNGX | BlackRock Inc. BLK | 5,457,030 5.000% | 5,457,030![]() (New Position) | Filing History |
| 2025-06-13 5:25 pm Purchase | 2025-06-06 | 13G | Tango Therapeutics, Inc. TNGX | Farallon Capital Partners L.P. | 7,182,000 6.600% | 7,182,000![]() (New Position) | Filing History |

